[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"A plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.\"","after":"\"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.\""}]},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Newly diagnosed\", approach: \"Dara-VRd ± ASCT → lenalidomide maintenance.\", refs: [\"whole-body-mri\"] },\n      { setting: \"Relapsed\", approach: \"CAR-T or bispecific; belantamab combinations; sequenci...","after":"[\n      { setting: \"Newly diagnosed\", approach: \"Dara-VRd ± ASCT → lenalidomide maintenance.\", refs: [\"whole-body-mri\"], guideline: { version: \"NCCN Guidelines: Multiple Myeloma\", url: \"https://www.nccn.org/guidelines..."}]},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/cancers.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"group"},{"field":"wikipedia"},{"field":"burden"},{"field":"tldr"},{"field":"summary"},{"field":"biomarkers"},{"field":"standardOfCare"},{"field":"stateOfArt"},{"field":"history"},{"field":"pipeline"},{"field":"openProblems"},{"field":"targets"},{"field":"technologies"},{"field":"tags"}]}]